Market Closed -
Nasdaq
21:30:00 08/05/2024 BST
|
5-day change
|
1st Jan Change
|
1.31
USD
|
-4.38%
|
|
-3.68%
|
-59.57%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
18.51
|
70.14
|
86.9
|
22.89
|
14.05
|
7.169
|
-
|
-
|
Enterprise Value (EV)
1 |
18.51
|
29.58
|
86.9
|
22.89
|
14.05
|
7.169
|
7.169
|
7.169
|
P/E ratio
|
-0.9
x
|
-1.04
x
|
-2.43
x
|
-0.51
x
|
-
|
-0.12
x
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-3,487,299
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
173
|
1,601
|
3,811
|
3,811
|
4,338
|
5,472
|
-
|
-
|
Reference price
2 |
107.2
|
43.80
|
22.80
|
6.006
|
3.240
|
1.310
|
1.310
|
1.310
|
Announcement Date
|
14/05/20
|
31/03/21
|
08/04/22
|
10/04/23
|
16/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-20.11
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-7.77
|
-20.15
|
-30.4
|
-43.62
|
-
|
-55.32
|
-76.09
|
-90.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-7.946
|
-20.32
|
-32.72
|
-45.08
|
-49.34
|
-51.55
|
-76.09
|
-90.5
|
Net income
1 |
-6.719
|
-20.36
|
-32.72
|
-45.34
|
-48.93
|
-51.55
|
-76.09
|
-90.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-119.0
|
-42.00
|
-9.400
|
-11.80
|
-
|
-10.72
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
14/05/20
|
31/03/21
|
08/04/22
|
10/04/23
|
16/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-9
|
-7.252
|
-20
|
-8.465
|
-7.902
|
-13.21
|
-14.17
|
-10.66
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-9.733
|
-6.93
|
-19.91
|
-8.548
|
-9.695
|
-13.26
|
-14.08
|
-10.53
|
-11.47
|
-
|
-
|
-
|
-
|
Net income
|
-9.267
|
-9.733
|
-6.93
|
-19.91
|
-8.548
|
-9.949
|
-13.26
|
-14.08
|
-10.53
|
-11.06
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
1 |
-2.400
|
-2.600
|
-1.800
|
-5.200
|
-2.200
|
-2.600
|
-3.480
|
-3.680
|
-2.740
|
-
|
-3.600
|
-3.710
|
-1.900
|
-1.970
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
08/04/22
|
16/05/22
|
15/08/22
|
14/11/22
|
10/04/23
|
12/05/23
|
14/08/23
|
20/11/23
|
16/04/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
40.6
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
14/05/20
|
31/03/21
|
08/04/22
|
10/04/23
|
16/04/24
|
-
|
-
|
-
|
Last Close Price
1.31
USD Average target price
30
USD Spread / Average Target +2,190.08% Consensus |
1st Jan change
|
Capi.
|
---|
| -59.57% | 7.5M | | +2.93% | 106B | | +7.02% | 23.47B | | -14.60% | 21.9B | | -7.05% | 18.77B | | -38.55% | 17.85B | | -8.83% | 16.78B | | +5.51% | 14.41B | | +37.49% | 12.86B | | +329.39% | 8.78B |
Bio Therapeutic Drugs
|